BACKGROUND: Longer disease duration is associated with inferior response to biologic therapy in Crohn's disease. However, the effect of disease duration on response to biologic therapy in ulcerative colitis (UC) has not been well studied. METHODS: In a single-center retrospective cohort study of outpatients with UC starting a biologic agent, we evaluated treatment response by disease duration. The primary outcome was treatment failure (composite outcome of inflammatory bowel disease [IBD]-related surgery/hospitalization or treatment modification including dose escalation, treatment discontinuation, or addition of corticosteroids); secondary outcomes were risk of IBD-related surgery/hospitalization and endoscopic remission. We conducted multivariate Cox proportional hazard analyses to evaluate the independent impact of disease duration on clinical outcomes. RESULTS: We included 160 biologic-treated UC patients (73% biologic-naïve) with a median age (interquartile range) of 36 (26-52) years and disease duration (range) of 4.5 (1-9) years. After adjusting for immunosuppressive medications, albumin, and body mass index, each 1-year increase in disease duration was associated with a 5% lower risk of treatment failure (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.91-0.99) and a 9% higher risk of achieving endoscopic remission (adjusted odds ratio, 1.09; 95% CI, 1.01-1.18). This association of short disease duration with treatment failure was observed only in biologic-naïve patients, but not biologic-experienced patients. No significant association was seen between disease duration and risk of surgery or hospitalization. CONCLUSION: Shorter disease duration is independently associated with increased risk of treatment failure in biologic-treated patients with UC. Requirement of biologic therapy early in the course of disease may be a negative prognostic marker in patients with UC.
BACKGROUND: Longer disease duration is associated with inferior response to biologic therapy in Crohn's disease. However, the effect of disease duration on response to biologic therapy in ulcerative colitis (UC) has not been well studied. METHODS: In a single-center retrospective cohort study of outpatients with UC starting a biologic agent, we evaluated treatment response by disease duration. The primary outcome was treatment failure (composite outcome of inflammatory bowel disease [IBD]-related surgery/hospitalization or treatment modification including dose escalation, treatment discontinuation, or addition of corticosteroids); secondary outcomes were risk of IBD-related surgery/hospitalization and endoscopic remission. We conducted multivariate Cox proportional hazard analyses to evaluate the independent impact of disease duration on clinical outcomes. RESULTS: We included 160 biologic-treated UCpatients (73% biologic-naïve) with a median age (interquartile range) of 36 (26-52) years and disease duration (range) of 4.5 (1-9) years. After adjusting for immunosuppressive medications, albumin, and body mass index, each 1-year increase in disease duration was associated with a 5% lower risk of treatment failure (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.91-0.99) and a 9% higher risk of achieving endoscopic remission (adjusted odds ratio, 1.09; 95% CI, 1.01-1.18). This association of short disease duration with treatment failure was observed only in biologic-naïve patients, but not biologic-experienced patients. No significant association was seen between disease duration and risk of surgery or hospitalization. CONCLUSION: Shorter disease duration is independently associated with increased risk of treatment failure in biologic-treated patients with UC. Requirement of biologic therapy early in the course of disease may be a negative prognostic marker in patients with UC.
Authors: William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar Journal: Gastroenterology Date: 2011-11-04 Impact factor: 22.682
Authors: Sabina A V Mir; Dorottya Nagy-Szakal; Elliot O'Brian Smith; Mark A Gilger; Richard Kellermayer Journal: J Clin Gastroenterol Date: 2014-03 Impact factor: 3.062
Authors: Sanjay K Murthy; Gordon R Greenberg; Kenneth Croitoru; Geoffrey C Nguyen; Mark S Silverberg; A Hillary Steinhart Journal: Inflamm Bowel Dis Date: 2015-09 Impact factor: 5.325
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: S Kugathasan; L J Saubermann; L Smith; D Kou; J Itoh; D G Binion; A D Levine; R S Blumberg; C Fiocchi Journal: Gut Date: 2007-08-06 Impact factor: 23.059
Authors: Levente Parragi; N Fournier; Jonas Zeitz; Michael Scharl; Thomas Greuter; Philipp Schreiner; Benjamin Misselwitz; Ekaterina Safroneeva; A M Schoepfer; Stephan R Vavricka; Gerhard Rogler; Luc Biedermann Journal: J Crohns Colitis Date: 2018-06-28 Impact factor: 9.071
Authors: David M Faleck; Adam Winters; Shreya Chablaney; Preeti Shashi; Joseph Meserve; Aaron Weiss; Satimai Aniwan; Jenna L Koliani-Pace; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Varun Kesar; Karen Lasch; Michelle Luo; Matthew Bohm; Sashidhar Varma; Monika Fischer; David Hudesman; Shannon Chang; Dana Lukin; Keith Sultan; Arun Swaminath; Nitin Gupta; Corey A Siegel; Bo Shen; William J Sandborn; Sunanda Kane; Edward V Loftus; Bruce E Sands; Jean-Frederic Colombel; Parambir S Dulai; Ryan Ungaro Journal: Clin Gastroenterol Hepatol Date: 2019-01-06 Impact factor: 11.382
Authors: Fernando Magro; Catarina Alves; Mafalda Santiago; Paula Ministro; Paula Lago; Luís Correia; Raquel Gonçalves; Diana Carvalho; Francisco Portela; Cláudia Camila Dias; Axel Dignass; Silvio Danese; Laurent Peyrin-Biroulet; Maria Manuela Estevinho; Paula Moreira Journal: United European Gastroenterol J Date: 2021-12-14 Impact factor: 4.623